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BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] This present invention is directed to cell culture
and, more particularly, to a three-dimensional culture and
harvest system for anchorage-dependent cells.
DESCRIPTION OF RELATED ART
[0002] There has recently been a resurgence of inter-
est in stem cell research. Stem cells are multi-potent and
plastic, which enables them to be induced to differentiate
into various cell types. Almeida-Porada et al., "Adult
Stem Cell Plasticity and Methods of Detection," Rev Clin
Exp Hematol 5(1), 26-41 (2001). Adult stem (AS) cells
are preferable in most applications not only because the
cell sources are less controversial and more readily avail-
able than embryonic stem (ES) cells, but also the adult
stem cells are more easily induced into the final differen-
tiated cell types needed in applications. Clarke, D. et al.,
"Differentiation Potential of Adult Stem Cells," Curr Opin
Genet Dev 11(5), 575-580 (2001). To date, AS cells are
not considered suitable substitutes for ES cells because
of the differences in their proliferation capacity in vitro.
Gage, F. H., "Mammalian Neural Stem Cells," Science
287 (5457), 1433-1438 (2000); NIH bioethics guideline.
ES cells (especially in murine models) have essentially
unlimited proliferation capacity in vitro, which means that
they can be expanded greatly for applications. On the
other hand, most AS cells can only proliferate for about
5-12 passages in vitro and then stop proliferating, but
randomly differentiate into other cell types. Pittenger, M.
F. et al., "Multilineage Potential of Adult Human Mesen-
chymal Stem Cells," Science 284 (5411), 143-147
(1999). This characteristic has heretofore severely limit-
ed the usefulness of AS cells in therapeutic applications.
[0003] Most mammalian cells are anchorage-depend-
ent (except cells in fluid, such as lymphatic and hemat-
opoietic cells). In vitro culture of the anchorage-depend-
ent cells traditionally has been limited by two primary
factors. One is the limited space of the culture vessels.
Cells will only proliferate exponentially in log phase when
there is adequate room in the culture vessels. Once the
cells establish contact with each other, their proliferation
slows down and eventually stops or the cells even signal
each other to die by apoptosis. The other limiting factor
is the suitability of substrates for cell attachment Inap-
propriate attachment often alters the cellular functions
and all the observed structures and functions thereafter.
Both factors cause potential artifacts that can affect the
outcome of cell biological studies or cell-transplantation
or tissue engineering applications.
[0004] An approach of improving the degree to which
the space of a culture vessel is utilized, is the use of
microcapsules. U.S. patent application 5,620,883 dis-
closes biocompatible microcapsules containing living
cells encapsulated in a membrane. According to this doc-
ument, the membrane is permeable to material required
for normal cell function and products released from cells.
[0005] Chia et al. describe in Tissue Engineering 6 (5),
481-495 (2000), a reference which has been published
after the priority date of the present application, a method
of encapsulating rat hepatocytes in microcapsules. The
microcapsules used by Chia et al. were permeable only
to small molecules and had a 2- to 3 -mm outer layer of
synthetic polymer and an inner layer of positively charged
modified collagen.
[0006] Several approaches have been used to avoid
contact inhibition of cell proliferation by providing suffi-
cient space or surface on which the cells can grow. One
approach has been to split cells by protease treatment
to detach the cells from the culture surface before the
cell-density becomes confluent Trypsin is commonly
used but others, such as collagenase, are also used in
some circumstances. Protease-treated cells typically are
rounded up, collected, pelleted by centrifugation, re-sus-
pended in fresh culture media, and distributed in multiple
culture vessels. Each new vessel contains a fraction of
the original cell number, and thus has sufficient new sur-
face to allow cell proliferation until confluence again oc-
curs. Such a splitting process can be repeated several
times, until the cells stop proliferating due to other rea-
sons.
[0007] Another approach has been to increase the
time before successive cell splitting by lowering the min-
imum number of cells to be seeded into vessels or in-
creasing the maximum number of cells that the culture
vessel can accommodate before confluence. Because
cells naturally prefer to be in the vicinity of other cells to
support each other, the minimum number that can be
seeded initially in culture vessel is often limited by the
support rendered by cell-cell interaction, communication
and the release of growth factors and the like. Therefore,
enriched culture media have been used to support cell
growth and proliferation, allowing lower minimum cell
number to be seeded in the vessel, and allowing a longer
period before the cells have to be split again.
[0008] Another way of increasing the time of culture
between each split has been to grow cells in three-di-
mensional matrix. A three-dimensional matrix typically
has a thick layer of matrix such as collagen on the surface
of culture vessel, or microspheres of concentrated ma-
trix. In such a three-dimensional matrix, cells can grow
into multiple layers in 3 dimensions, thereby permitting
a longer culture period before confluence. To modulate
cell attachment to a substrate, various natural and syn-
thetic substrates have been developed such as those
involving short-peptides and sugar-motifs and the like.
[0009] Essentially all these approaches involve split-
ting cells with disruptive techniques such as proteases,
cold treatment, or EDTA treatment combined with cell
scraping to detach the cells from the substrate (either
charged surfaces or three-dimensional matrix). Either of
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these splitting techniques can have detrimental effects
on cell structure and function. For example, proteases
digest away cell surface molecules that are essential not
only for cell attachment to substrates but also for signal-
ing molecules that are important for cell function. Cold
treatment has been shown to adversely affect various
cellular processes such as cytoskeleton arrangement,
membrane trafficking pathways, and the like. EDTA treat-
ment and mechanical scraping has been shown to ad-
versely affect cell functions because the cells round up
and are prone to damage by mechanical scraping. In the
case of three-dimensional culture in matrix, protease
treatment is the only way presently known to split cells.
For cell transplantation or cell seeding onto tissue-engi-
neered scaffolds, cells with temporarily damaged func-
tions (due to disruptive cell splitting techniques) are cur-
rently being used because the current culture methods
cannot offer a better alternative.
SUMMARY OF THE INVENTION
[0010] The present invention is directed to a non-dis-
ruptive three-dimensional system for culturing one or
more anchorage-dependent cell types.
[0011] The system comprises a plurality of hollow mi-
crocapsules, each containing an inner extracellular ma-
trix in contact with at least one cell and an outer shell of
synthetic polymer surrounding the extracellular matrix.
Cells in contact with the extracellular matrix are cultured
in three dimensions inside of the hollow microcapsules.
The microcapsules are permeable to nutrients necessary
to sustain normal metabolic functions of the cells and to
toxins released by the cells. The outer shell has a thick-
ness of from about 1 to about 20 mm and is rupturable
with mechanical agitation to harvest the cultured cells.
[0012] The three-dimensional culture system allows
cell growth and proliferation in three dimensions, allowing
cell splitting without subjecting cells to disruptive condi-
tions that affect cell structure and functions. The matrix
used in the system also provides a good environment for
culturing or co-culturing anchorage-dependent cells. The
cells cultured this manner can be readily used in cell
transplantation, tissue engineering seeding of cells on
scaffolds, and other applications that require immediate
availability of functioning cells. The culture system of the
present invention employs mechanically fragile micro-
capsules that easily break during the cell splitting proc-
ess. The positively charged collagen preferably is opti-
mized to be sufficiently diluted inside microcapsules,
such that the collagen can be easily rinsed away from
cells during cell splitting.
[0013] The non-disruptive three-dimensional cell cul-
ture system allows anchorage-dependent cells to be cul-
tured in the microcapsules and to be harvested without
the need of subjecting the cells to harsh treatment such
as proteases, cold or cell scraping. The harvested cells
cultured this way are readily used for cell transplantation
or cell seeding onto scaffold for tissue engineering ap-
plications. Cells cultured with current systems, in con-
trast, are somewhat damaged by the harvest procedure.
[0014] The three-dimensionality of the system is de-
signed to amplify large number of cells with reduced cell
splitting frequency. The system also allows harvest of
cells for re-proliferation or for immediate use in applica-
tions without undergoing the typical detachment proce-
dures. The cells harvested non-disruptively from the cell
culture system of the present invention typically exhibit
improved attachment kinetics, better-preserved cell mor-
phology and functions than conventionally cultured cells
when binding to ligand-conjugated polymer surfaces.
[0015] The cell culture system of the present invention
is useful in cell-based analyses or diagnostic methods,
such as flow cytometry analyses, that depend on the cell
surface markers. Currently, such analyses are only ap-
plicable to suspension cells such as hemopoietic cells.
Examples include using Annexin V as marker for apop-
tosis, Ca++ kinetics or cytoskeleton markers that are sen-
sitive to cell harvesting conditions such as protease, cold
or EDTA treatments. The present invention enables
these analyses to be applied to all other cell types that
are anchorage-dependent.
[0016] Three-dimensional culture is more like the nat-
ural setting of cells, which is demonstrated by higher level
of cell functions than those from two-dimensional culture.
There is also more room for cells to proliferate, thereby
increasing culture time before cell splitting is necessary.
This also results in smaller number of seeded cells and
larger number of harvested cells. Such characteristics
are ideal for large-scale cell production. Previous three-
dimensional methods are hampered by the difficult cell
splitting and harvesting procedures. The present inven-
tion overcomes the drawbacks of previous three-dimen-
sional methods.
[0017] Because the use of enzyme, chemicals or tem-
perature change is not needed in the three-dimensional
cell culture system during cell splitting, the process of the
cell splitting is greatly simplified and the cost and storage
of enzymes used to split cells can be minimized. This is
particularly advantageous for large-scale production and
passage of anchorage-dependent cells.
[0018] Each microcapsule serves as an independent
micro-chamber for cell culture, thus allowing the micro-
capsules to be used in any bioreactor design. The mass
transport property of the microcapsules is good enough
to allow cell culture in even stationary culture vessels.
This can be achieved, for example, with a low concen-
tration of the extracellular matrix. Where collagen is used
as an extracellular matrix, for example, the concentration
typically ranges from about 0.2 to about 3.5 mg/ml. In
previous systems using collagen as matrix, higher con-
centrations of collagen (4-5 mg/ml) were used because
it was necessary to have the collagen gel and form the
shape of the spherical droplet, and then coated with poly-
L-lysine. Higher concentrations of the extracellular matrix
tend to have skin effect that impedes the mass transport
properties. Therefore, the previous microcapsules must
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be used in fluidized bed bioreactor to achieve improved
mass transport for sufficient nutrient and gas supply for
cell culture. The microcapsules of the present invention
can be used with any bioreactor design. Especially in the
case of packed bed, the culture media volume used can
be kept at minimum.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The present invention will now be described in
more detail with reference to preferred embodiments of
the invention, given only by way of example, and illus-
trated in the accompanying drawings in which:
FIG. 1 is a graph illustrating PC 12, HepG2, and mes-
enchymal stem (MSc) cells being greatly amplified
in the microcapsules without splitting;
FIGS. 2A-2B illustrate "conformer scaffolds" formed
around individual cells and allow cell splitting or har-
vesting without detachment from the substrata:
FIG. 2A is a graph illustrating collagen gelation
measured at 37˚C by the increase in refractive index;
FIG. 2B is a confocal image showing collagen la-
beled with FITC;
FIG. 3 is a scanning electron microscope (SEM) im-
age of a microcapsule in which a portion of a micro-
capsule was peeled off exposing the cells encapsu-
lated inside;
FIG. 4 is a graph illustrating cell re-proliferation of
PC 12, HepG2 and MSc cells in the microcapsules;
and
FIGS. 5A-5F illustrate comparison of ligand-specific
attachment, cell morphology, and functions of the
un-disrupted cells, and conventionally cultured cells:
FIG. 5A is a graph illustrating attachment of PC 12
cells onto YIGSR conjugated to polyester cover slip;
FIG. 5B is a graph illustrating attachment of rat hepa-
tocytes on lactose-conjugated polyester membrane;
FIG. 5C illustrates the morphology and function of
the PC 12 cells; FIG. 5D is a graph illustrating the
detoxification function of the rat hepatocytes; FIG.
5E are images showing morphology and proliferation
capacity assessment of the MSc cells after a month
of continuous culture; and FIG. 5F illustrates the dou-
bling time of undisrupted cells and of conventionally
cultured cells.
DETAILED DESCRIPTION OF THE INVENTION
[0020] The three-dimensional cell culture system of
the present invention employs fragile microcapsules with
a controlled three-dimensional microenvironment for op-
timal cell growth, proliferation and function. Microcap-
sules in the form of spheres have the highest surface
area-to-volume ratio, and preferably have an ultrathin
shell allowing good mass-transport properties, thereby
avoiding central necrosis resulted from nutrient/oxygen
starvation as typically is observed in present three-di-
mensional culture configurations. In a preferred config-
uration of the present invention, essentially the only role
of the outer shell is to provide a container to hold the
extra-cellular matrix inside the spherical shape to provide
a substrate for the cells. To this end, a minimal concen-
tration of the matrix sufficient to support cell growth, pro-
liferation and function can be employed. For example,
when collagen is used as an extracellular matrix, the con-
centration typically ranges from about 0.2 to about 3.5
mg/ml, and more typically from about 0.5 to about 1.5
mg/ml, in contrast to the 4 to 5 mg/ml typically used to
entrap cells in present three-dimensional culture config-
urations.
[0021] Among the principal advantages associated
with the three-dimensional cell culture system of the
present invention are those exhibited in cell splitting and
cell harvesting. Advantageously, the matrix does not
need to gel to hold the cells in place. Therefore, when
the fragile shells are broken at the time of cell splitting,
the dilute matrix can be easily removed from cells by
pelleting the cells and rinsing them with fresh culture me-
dia or buffers. The cells can be split into small fractions,
diluted with new matrix and be microencapsulated and
cultured again. The process can be repeated without sub-
jecting cells to any harsh conditions that are disruptive
to cell structures and functions. The cells are healthier
than those cultured in conventional systems due to a
more natural and constant culture environment without
the need for subjecting the cells to periodic harsh treat-
ments. Oxygen concentration often is the limiting factor
in such three-dimensional cell culture. The microcapsule
preferably should be less than about 200mm in diameter.
[0022] The fragility of the microcapsules is an impor-
tant aspect of the non-disruptive three-dimensional cul-
ture system. Weak mechanical force, such as pipetting
up and down a few times, generally is sufficient to break
the microcapsules and release the microcapsule con-
tents, e.g., the matrix and the cells. Cells then can be
separated from the dilute matrix by rinsing with buffers
or culture media. The fragility of the microcapsules can
be accomplished by employing a very thin microcapsule
shell. The microcapsule shell usually has a thickness up
to about 40 mm, often from about 1 to about 20 mm, and
even more often from about 2 to about 5 mm.
[0023] A wide variety of anchorage-dependent cells
can be used with the three-dimensional cell culture sys-
tem of the present invention. PC-12, a rat pheochromo-
cytoma cell that is normally cultured on collagen and
which has the ability to be induced into neuron-like cells,
is one example of an anchorage-dependent proliferating
cell. As another example, hepatocytes are very environ-
mentally sensitive anchorage-dependent cells. HepG2
is an example of a human hepatocellular carcinoma cell.
Mesenchymal stem (MSc) cells are multipotent cells that
can replicate as undifferentiated cells and that have the
potential to differentiate to lineages of mesenchymal tis-
sues. Other cells that have very strong cell-cell and cell-
matrix interaction, such as keratinocytes, also are useful
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with the culture system of the present invention. The
three-dimensional system of the present invention is par-
ticularly useful for the expansion of cocultures, e.g., by
including one than one cell type in the microcapsules.
[0024] The three-dimensional cell culture system of
the present invention is useful in a variety of tissue en-
gineering and cell transplantation applications, such as
enzyme-free culture and expansion of keratinocytes for
skin, or chondrocyte or mesenchymal stem cells for car-
tilage/bone. In addition, the culture system is useful in
applications that require or prefer three-dimensional cul-
ture of anchorage-dependent cells for either research
purposes or for the production of eukaryotic cells or cell-
secreted products. The culture system can be used in ex
vivo cell production and genetic modifications of cells for
transplantation therapies to treat cancer, infectious dis-
eases and tissue restoration. The culture system also is
useful in cell-based diagnostic or analysis that depends
on the natural states of cells (either from normal or path-
ological samples) without subjecting the cells to harsh
protease treatments.
[0025] Cells can be cultured in the microcapsules with
the matrix inside, while mass transport properties are
optimized to avoid central necrosis. Typically, about 1 x
105 cells are seeded inside the microcapsules. The cells
typically are allowed to proliferate for a period of days,
usually 7 to 9. At the end of a culture cycle, the ratio of
the final cell number to the initial seeded cell number
typically is at least 10, and more typically at least 20. The
ratio can be as higher as 100, 200, 400, 600, or more.
This ratio demonstrates a much longer time (8-9 days)
of cell culture between each successive cell splitting as
compared to conventional two-dimensional culture (2
days assuming the same cell doubling time of 24 hours).
The culture media should be changed every 2-3 days to
provide fresh supply of nutrients and to remove metabolic
wastes. Depending on the mechanical strength of the
microcapsules, the cells can be cultured in stationary
vessels or in packed bed for reduced consumption of
culture media in large-scale cell culture. In the latter case,
simple apparatus and minimum culture media can be
employed for large-scale production of anchorage-de-
pendent cells.
[0026] Both naturally-occurring and modified biopoly-
mers are suitable for use as the extracellular matrix in
the practice of the invention, as are both cationic and
anionic biopolymers. In general, any commonly used
substrates in cell studies can be used, non-limiting ex-
amples of which include collagen, cationic collagen, an-
ionic collagen, anionic esterified hyaluronic acid, anionic
amine-modified hyaluronic acid, fibronectin, and laminin.
The biopolymers preferably are water-soluble and most
often have a molecular weight of at least 20,000, prefer-
ably at least 75,000, more preferably at least 125,000,
even more preferably at least 200,000, and yet even
more preferably at least 250,000.
[0027] Whereas collagen has been used to encapsu-
late drugs, it has not found widespread use for encapsu-
lating cells because, at neutral pH, there is insufficient
charge density to form an encapsulating membrane.
However, collagen modified to raise its pKi to at least
about 9 is sufficiently positively charged at physiological
pH to be complexed with oppositely-charged synthetic
polyelectrolytes to form a coherent membrane. Collagen
can be modified to form a more strongly basic polymer
by converting the primary amino groups to tertiary amine
groups or by esterification.
[0028] Anionic biopolymeric materials, such as hy-
aluronic acid (HA) and modified HA (esterified HA or
amine-modified HA) are useful in the invention. In gen-
eral, anionic biopolymers suitable for the practice of this
invention will have a charge density of at least about 20%,
preferably at least about 30%, and even more preferably
at least about 50%. HA that is totally or partially esterified
or reacted with a primary amine to render it less water-
soluble will form a stronger complex with the polycationic
outer layer than HA itself. Preferred biopolymers for form-
ing the extracellular matrix include modified HA and mod-
ified collagen. Esterified collagen is particularly pre-
ferred. In general, the extracellular matrix, though water-
soluble, will be slightly hydrophobic.
[0029] Esterification or reaction to form tertiary amine
groups on the biopolymer may be accomplished by re-
action of the biopolymer with a wide variety of aliphatic
reactants containing as many as about 18 carbon atoms
in their chain. Such reactants include, inter alia, alcohols,
primary amines and alcohol amines. Preferred reactants
contain about 8 carbon atoms or less. For some purpos-
es, use of reactants having only 2 or 3 carbon atoms may
be preferred. Typical alcohols include methanol, ethanol,
butanol and higher alcohols, whereas typical primary
amines include methylamine, ethylamine and higher
amines. Reactants with both alcohol and amine groups
also can be used, such as ethanolamine. Reactants
should be chosen so as to not impair the viability of the
cells.
[0030] The outer shell comprises a biocompatible syn-
thetic polyelectrolyte having a charge opposite that of the
biopolymer. Thus, when the biopolymer is polycationic
(e.g., modified collagen), the synthetic polyelectrolyte
used in the outer layer should be polyanionic. Converse-
ly, when the biopolymer is polyanionic (e.g., HA, modified
HA, etc.), the synthetic polyelectrolyte used in the outer
shell should be polycationic. Suitable outer layer synthet-
ic polyelectrolytes form a complex with the oppositely-
charged biopolymer to form a membrane by the complex
coacervation process and impart stability to the encap-
sulate. The charge density of the synthetic polymer typ-
ically will be from about 0.1 % to about 20%, preferably
is at least about 1%, and even more preferably is at least
about 3%. Like the biopolymers, the synthetic polyelec-
trolytes preferably have a molecular weight of at least
20,000, preferably at least 75,000, more preferably at
least 125,000, even more preferably at least 200,000,
and yet even more preferably at least 250,000.
[0031] The biocompatible synthetic polyelectrolyte
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layer that is capable of forming, with the biopolymer of
the extracellular matrix, a membrane which allows envi-
ronmentally-sensitive living cells, such as hepatocyte
cells, to remain viable and, at the same time, protects
the cells against immunological rejection by the host. A
preferred class of biocompatible synthetic polyelectro-
lytes is acrylate polymers. Such polymers include acr-
ylate polymers, copolymers and ter-polymers such as
poly(acrylic acid), poly(methacrylic acid), poly(methacr-
ylate), poly(methyl methacrylate), and acrylate copoly-
mers and ter-polymers of acrylic acid, methacrylic acid,
methacrylates, methyl methacrylates, hydroxyethyl
methacrylic such as 2-hydroxyethyl methacrylate, hy-
droxypropyl-acrylate and the like, and blends thereof. Po-
ly(dimethylaminoethyl methacrylate) (DMAEMA) and co-
polymers and ter-polymers of dimethylaminoethyl meth-
acrylate with 2-hydroxyethyl methacrylate and/or hydrox-
ypropylacrylate and methacrylate and/or methyl meth-
acrylate are preferred cationic synthetic polymers. Co-
polymers or ter-polymers of acrylic acid and/or meth-
acrylic acid with 2- hydroxyethyl methacrylic and/or hy-
droxypropylacrylate and methacrylate and/or methyl
methacrylate are preferred anionic synthetic polymers.
Each has exhibited biocompatibility when used in other
biomaterials.
[0032] A preferred biocompatible synthetic polyelec-
trolyte outer shell is an acrylate ter-polymer of methacryl-
ic acid (MAA), hydroxyethyl methacrylate (HEMA), and
methyl methacrylate (MMA). The ter-polymer preferably
comprises from about 10 mol% to about 30 mol%, more
preferably from about 15 mol% to about 25 mol% MAA,
from about 10 mol% to about 40 mol%, more preferably
from about 20 mol% to about 30 mol% HEMA, and from
about 20 mol% to about 60 mol%, more preferably from
about 45 mol% to about 55 mol% MMA. In a preferred
embodiment of the present invention, the ter-polymer is
formed by polymerizing MAA, HEMA, and MMA mono-
mers in about a 1:1:2 molar ratio.
[0033] The membrane of the encapsulated cell is se-
lectively permeable. The cells encapsulated in accord-
ance with the invention remain viable because the mem-
brane is permeable to nutrients and other materials nec-
essary to support the normal metabolic functions of the
cells. Thus, ionic materials and oxygen, for example,
pass through the membrane. The membrane also is per-
meable to products of the cells, such as hormones, and
to metabolic byproducts. Thus, material produced by the
cell can pass through the membrane from the interior of
the microcapsule. In this way, material produced by the
encapsulated cell can be introduced into the blood of a
host, or can be introduced into a culture medium in which
encapsulated cells are placed.
[0034] The membrane permeability essentially pre-
cludes entry of immunoglobulins, macrophages, and oth-
er immune system agents that cause rejection of cells
by the host’s immune system. According to a preferred
embodiment of the invention, the membrane is imperme-
able to molecules greater than about 100 kDa, and pref-
erably is impermeable to molecules greater than about
71 kDa. According to another preferred embodiment of
the invention, the membrane is permeable to molecules
greater than about 60 kDa and impermeable to molecules
greater than about 150 kDa.
[0035] The composition of the outer shell can be mod-
ified to adjust the permeability and transport properties
of the membrane. As an example, the permeability of the
membrane to typically polar compounds found in biolog-
ical systems can be increased by incorporating a hy-
drophilic copolymer, such as poly(2-hydroxyethyl meth-
acrylate) (HEMA) or other hydroxy-containing acrylates,
into the polyelectrolyte which forms the outer layer of the
membrane. Increasing hydrophobicity of polyelectrolytes
tends to cause decreased permeability.
[0036] In the preferred MAA/HEMA/MMA ter-polymer,
HEMA provides hydrophilicity to render the ter-polymer
water-soluble so that the entire encapsulation can be per-
formed in the physiological aqueous buffer without the
need for an organic solvent. MMA imparts mechanical
strength, toughness, and elasticity to the microcapsules.
MAA provides a negative charge to interact with a posi-
tively charged inner layer. The inner layer preferably is
an esterified collagen with net positive charge. The bal-
ance between the two charged polymers determines the
physical characteristics of the microcapsules. Using a
10% ter-polymer and 1.5 mg/ml of modified collagen, for
example, microcapsules can be formed having a thin lay-
er of outer shell (~ 2 mm) and a semi-gel-like inner layer
that minimizes impedance to mass transport across the
membrane but remain stable as microcapsules for days.
The semi-gel-like inner collagen layer is able to provide
a "loose" extracellular matrix configuration that mimics
the in vivo situation, therefore allowing the microcapsule
to maintain higher levels of cell function. These charac-
teristics of the microcapsules that satisfy most require-
ments for a bioartificial liver-assisted device (BLAD) were
achieved through optimization of several parameters.
[0037] The permeability of the membrane also can be
adjusted by selection of molecular weight or structure of
the outer shell so as to preclude molecules having a
preselected molecular weight or structure from passing
through the membrane. As the molecular weight of the
polyelectrolyte is increased, the membrane tends to be
more permeable. Larger differences in charge densities
between the inner biopolymer and the outer polyelectro-
lyte also tend to make the membrane more permeable.
The mechanical stability of the membrane can be im-
proved by increasing the molecular weight of the polye-
lectrolyte in the outer shell or by employing monomers
in the polyelectrolyte that provide mechanical strength,
such as MMA.
[0038] The membrane can be formed by complex
coacervation by combining drops of a solution of biopol-
ymer containing a cell suspension with a solution of syn-
thetic polymer at physiological or neutral pHs of from
about 6 to about 8 so as to avoid adversely affecting the
viability of the cells. In such process, the biopolymer is
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dissolved in a suitable aqueous solvent that will not ad-
versely affect the viable cells. Such solvents are well
known and include buffered saline, culture medium and
the like. Similarly, the synthetic polyelectrolyte is soluble
in and dissolved in a suitable solvent that will not threaten
the viability of the cells. Such solvents include aqueous
solvents such as buffered saline, culture medium and the
like. The solvent used for the biopolymer does not need
to be the same solvent used for the synthetic polymer.
Mild agitation of the polyelectrolyte solution can be uti-
lized if desired.
[0039] In one suitable technique, a substrate polymer
solution containing a cell suspension in a suitable diluent
such as phosphate buffered saline (PBS) is added drop-
wise to a receiving solution containing synthetic polye-
lectrolyte of the opposite charge in PBS at ambient tem-
perature. A cohesive membrane is formed at the interface
of the two solutions to provide encapsulated cells. Ad-
vantageously, no organic solvent is required and no
cross-linking reaction is necessary. Thus, the conditions
of encapsulation are especially mild, yielding little cell
mortality.
[0040] The proper matching of biopolymer and syn-
thetic polyelectrolyte can be readily confirmed. A drop of
a solution of biopolymer can be added to a solution of
electrolyte. A proper match results in the rapid formation
of a microcapsule or membrane by complex coacerva-
tion, which can be observed visually. The suitability of a
given encapsulate regarding permeability can be readily
determined by in vitro tests using standard cell culture
media to determine if desired products are secreted, if
unwanted immune components are excluded, and if vi-
ability of encapsulated cells is suitably maintained.
[0041] The concentrations of the polymer solutions,
the size of the droplets added to the synthetic polyelec-
trolyte solution, and the rate at which the substrate pol-
ymer solution containing cell suspension is added to the
synthetic polyelectrolyte solution can be adjusted to
achieve an encapsulating membrane having the desired
thickness of layers and desired size. Suitable concentra-
tions for the biopolymer solution and for the synthetic
polyelectrolyte solution will vary depending upon the spe-
cific polymers and solvents employed, but determination
of such concentrations is easily within the skill of the art.
While it is not possible to delineate concentrations for all
possibilities, the concentration of the biopolymer often
will be from about 0.1 to 2% whereas the concentration
of the synthetic polyelectrolyte often will be from about
2 to 6%.
[0042] The thickness of the inner, substrate polymer
layer, will depend on, inter alia, the viscosity of the bi-
opolymer solution and the degree of penetration into the
synthetic polyelectrolyte solution achieved by the sub-
strate polymer solution droplets. The degree of penetra-
tion is related to the molecular weight of the polyions and
the viscosity of the solutions.
[0043] The number of cells within each microcapsule
can be readily controlled and is a function of the density
of the cell suspension within the biopolymer. For exam-
ple, cells in PBS (which may be at densities of 103 to 106
cells per ml) can be mixed with the biopolymer to provide
a variety of cell concentrations. Individual microcapsules
can contain any desired number of cells, typically ranging
from 1 to 200 cells or more. Collagen gel has been ob-
served to exhibit a "skin effect" that is detrimental to mass
transport, as a high concentration of collagen leads to
gelation. Such "skin effect" is concentration- and temper-
ature-dependent. Extra-cellular matrices like collagen or
Matrigel have gelling temperatures of ~22-35˚C depend-
ing on the concentration of these proteins. At 37˚C, where
hepatocytes are normally cultured in a bioreactor or
transplantation is performed in vivo, the "skin effect" can
be most pronounced. Since mass transport is among the
most important considerations for the design of bioreac-
tors in BLAD, it is desirable to employ the optimal con-
centration of collagen such that the "skin effect" is mini-
mized while there still is enough collagen to complex with
the synthetic polyanion forming stable microcapsules.
[0044] Albumin was used as a model molecule for the
permeability optimization of the microcapsules. Albumin
(MW ~ 67,000 Da) is one of the secreted proteins of hepa-
tocytes. It acts as a carrier to bind most metabolic wastes
in the liver for removal from the blood. Another major
scavenger protein is bilirubin (~10,000 Da), which is
smaller than albumin. Albumin was found to be freely
permeable to the microcapsules. A known concentration
(1% w/v) of albumin was added to collagen and micro-
capsules were formed. The microcapsules were equili-
brated in a culture medium with the same concentration
of albumin (1% w/v) at 37˚C for 2 hours to allow a possible
"skin effect" to occur. Such equilibration before the per-
meability measurements is essential for detecting any
"skin effect" from the gelling collagen. Pre-equilibration
for up to 5 days indicated that the "skin effect" was mar-
ginally more pronounced than with the 2 hour pre-equi-
libration. The albumin released from the microcapsules
into the fresh culture medium with no albumin added was
thereafter monitored. With 1.5 mg/ml of the modified col-
lagen, most of the encapsulated albumin was released
from the microcapsules within 15 minutes. As the con-
centration of collagen in the microcapsule was increased
to 4 mg/ml (~ 0.4% w/v), the release of albumin was great-
ly inhibited. For collagen concentration below 1.5 mg/ml,
hepatocytes could not be encapsulated, possibly due to
insufficient positive charge from the diluted collagen.
[0045] One preferred ter-polymer composition is made
up of 25 mol% HEMA, 25 mol% MAA and 50 mol% MMA
at a concentration of 10% in PBS. When the ter-polymer
composition was modified for higher negative charge at
the expense of mechanical stability (e.g., 50 mol% MAA,
25 mol% HEMA, 25 mol% MMA), the urea-synthesis of
the encapsulated hepatocytes decreases to levels below
the monolayer control. The polymer composition and
concentrations can be varied to achieve enhanced me-
chanical stability and other physical characteristics.
[0046] Because the membrane of the encapsulated
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cells of the invention precludes contact between the cells
and the host’s immune mediators, all types of living cells,
including both naturally-occurring and genetically-engi-
neered cells, may be encapsulated. The encapsulates
are suitable for anchorage-independent cells and are
particularly suitable for encapsulation of environmentally
sensitive, anchorage-dependent living cells such as
hepatocytes.
[0047] Encapsulated cells of the invention also are
useful as, for example, a hormone-producing system.
Use of cells microencapsulated in a selectively permea-
ble bio-polymeric membrane affords the opportunity to
provide artificial organs and other methods for improving
and restoring functions in people with physical disabili-
ties.
[0048] An example of one type of hormone-producing
cell is a cell of the anterior pituitary gland. Such cell ex-
cretes growth hormone that inter alia stimulates skeletal
growth. In accordance with the invention, encapsulated
naturally occurring anterior pituitary cells are useful in
stimulating skeletal growth in a host. The encapsulated
cells provide growth hormone produced by the cells and
introduced to the blood of a host through the encapsu-
lating membrane. Genetically-engineered microorgan-
isms also can produce growth hormone. Such microor-
ganisms, when encapsulated, may be used to provide
growth hormone to a host.
[0049] Encapsulated cells that secrete hormones also
may be suspended in a culture medium and will excrete
hormone over an extended period. Encapsulated insulin-
producing cells, for example, mammalian pancreatic al-
pha cells, beta cells, or intact islets of Langerhans, may
also be used as an artificial pancreas. Such encapsulated
cells can be implanted into a diabetic mammal and will
function in vivo to excrete insulin and other hormones in
response to host blood glucose concentration.
[0050] Other types of cells also may be beneficially
encapsulated. For example, encapsulated neurotrans-
mitter-secreting cells may be used to treat neurological
disorders such as Parkinson’s and Alzheimer’s diseases.
Similarly, chromaffin cell transplants may be used for al-
leviation of pain, especially chronic pain, and encapsu-
lated chondrocytes may be used for repair of muscu-
loskeletal defects. Skilled practitioners recognize the util-
ity of encapsulating living cells, and will be able to identify
still further cells suitable for encapsulation in accordance
with the invention.
[0051] Even though the membrane may be permeable
to proteases that can digest collagen and other biopoly-
mers used to form the inner layer of the membrane, it
has been found that the inner layer remains intact. With-
out being bound by any theory, it is believed that the
proteases cannot digest the modified collagen, HA, mod-
ified HA, or other biopolymer when the biopolymer is
complexed with the outer layer. This resistance can be
analogized to the resistance to solubilization of type I
collagen and to cross-linked collagen, such as is found
in heart valve tissue. Again, without wishing to be bound
by theory, it is postulated that the complexation shields
or changes the conformation of the cleavage site (be-
tween glycine and leucine), thus making the resulting
complexed biopolymer resistant to degradation.
[0052] The length of the period during which encapsu-
lated cells remain intact will depend upon the properties
of the medium in which the encapsulated cells are used
and upon the composition of the biopolymer and of the
synthetic polyelectrolyte. For example, encapsulated
cells used in a culture medium might be expected to re-
main intact for a longer period than encapsulated cells
introduced into a human or animal body. Also, the me-
chanical stability of the membrane can be improved by
increasing the molecular weight of the synthetic polye-
lectrolyte. Skilled practitioners will be able to determine
the length of the period during which encapsulated cells
remain intact in various media.
[0053] The three-dimensional culture system of the
present invention supports the proliferation of anchor-
age-dependent mammalian cells. Three exemplary an-
chorage-dependent mammalian cell types of interest are
(1) PC 12, a rat pheochromocytoma cell that is normally
cultured on collagen, (2) HepG2, a human hepatocellular
carcinoma cell, and (3) mesenchymal stem (MSc) cells,
which are multipotent cells that can replicate as undiffer-
entiated cells and that have the potential to differentiate
to lineages of mesenchymal tissues. As shown in Fig. 1,
all of these cell types can proliferate in the microcapsules.
The cells can proliferate, for example, when seeded at
the density range of about 5 x 104 to 2 x 106 cells/ml with
the optimal density at about 1 x 106 cells/ml, which yield-
ed over 100-fold cell amplification (defined as the final/
initial cell densities in microcapsules) in 7 days.
[0054] In comparison, cells on the conventional two-
dimensional surfaces coated with collagen (referred to
for simplicity as "2D culture") could only proliferate when
the cells were seeded within the narrower density range
of 1 x 105 to 7 x 105 cells per 35 mm dish. Below a cell
seeding density of about 1 x 105 cells/dish, the cells did
not proliferate and often detached from the collagen sur-
faces within two days. Above about 7 x 105 cells/dish,
the cells were essentially confluent in the 2D culture and
did not proliferate due to contact inhibition. The three-
dimensional microenvironment of the microcapsules is
more permissive for anchorage-dependent cells to pro-
liferate before encountering contact inhibition.
[0055] With a cell seeding density of about 1 x 106
cells/ml, the effects of different collagen concentrations
on the proliferation of the PC 12 and HepG2 cells in the
microcapsules were evaluated. It was found that cells
could proliferate in the collagen concentration range of
0.5-5.0 mg/ml, with the optimal concentration at about
1.5 mg/ml. In the experiments described below, 1 x 106
cells/ml of the PC12, HepG2 and MSC cells were cultured
in 1.5 mg/ml of collagen.
[0056] It was found that the three-dimensional culture
system with positively charged collagen minimizes cell
splitting. One of the ways to avoid disrupting cells too
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often in culture is to allow the cells to proliferate for as
long as possible before splitting. Since the microcapsules
can accommodate more anchorage-dependent cells
than the 2D culture within the same culture volume, the
microcapsules can potentially allow a longer period of
cell culture to achieve greater cell amplification before
cell splitting is needed. Indeed, PC 12, HepG2, and MSc
cells can be cultured for 7 days in the microcapsules of
the present invention before the cells filled the microcap-
sules and cell splitting became necessary. The longest
permissive culture time before cell splitting and the level
of cell amplification between each successive cell split-
ting depend on the proliferation rates of cells under the
culture conditions employed. In 7 days, PC 12, HepG2,
and MSc cells were amplified 13067, 5063, and 10068
folds, respectively, in the microcapsules, as compared
to the typical 2-10 folds of cell amplification and 2-3 week-
ly splitting in 2D culture, as shown in Fig. 1. The folds of
amplification (defined as the ratio of the final cell density
to the initial cell density) are shown in Fig. 1 (F/I). The
symbol■ represents the F/I values for cells cultured in
2D; the symbol represents the F/I values for cells
cultured in microcapsules with the slightly modified col-
lagen; and the symbol represents the F/I values for
cells cultured in microcapsules with highly modified col-
lagen. All three cells were amplified greatly in the micro-
capsules, but not in the 2D culture. The additional net
positive charges on the highly modified collagen alone
could double the amplification of cells cultured in micro-
capsules.
[0057] Because many cells are known to respond to
electric signals in the microenvironments, it is believed
that the net positive charges on the modified collagen
contribute to the observed higher level of cell amplifica-
tion in the microcapsules than the 2D culture. To dem-
onstrate this, different amounts of net positive charges
on the collagen were controlled by manipulating the tem-
perature and the time of the collagen modification. Using
a highly modified collagen (the preparation of which is
described below), greatly stimulated cell amplification
was observed. The PC 12, HepG2, and MSc cells were
amplified 295619, 17069, and 163612 folds, respec-
tively, in the microcapsules with the highly modified col-
lagen (Fig. 1). It is believed that the additional net positive
charges alone on the collagen matrix could double the
amplification of cells cultured in the microcapsules.
[0058] The cultured cells eventually must be split for
re-proliferation or harvested for immediate applications.
To minimize or avoid the cell damages caused by de-
tachment procedures commonly used in cell splitting or
harvesting, the culture system of the present invention
preferably allows cells to be separated from each other
but not from the supporting substrata. This is possible
because of two unique properties of the culture system,
namely, the positively charged modified collagen with re-
duced gelation (Fig. 2), and the fragile microcapsule shell
(Fig. 3). The upper part of the image of Fig. 3 shows the
intact portion of the microcapsule showing that a very
thin and fragile layer of the shell wraps around the en-
capsulated cells. The lower part of the image of Fig. 3
shows the broken portion of the microcapsule showing
that the encapsulated cells are supported by loose col-
lagen fibers.
[0059] As shown in Fig. 2A, the modified collagen with
net positive charges has a reduced level of gelation than
the natural collagen as measured in a refractive index
assay. The symbol (o) represents the natural collagen
(1.5 mg/ml); the symbol (h) represents slightly modified
collagen (1.5 mg/ml); the symbol (x) represents highly
modified collagen (1.5 mg/ml); the symbol (0) represents
slightly modified collagen (5 mg/ml); and the symbol (+)
represents highly modified collagen (5 mg/ml). The pos-
itive charges on the modified collagen inhibit the collagen
gelation. In such an assay, 1.5 mg/ml of the native col-
lagen started exhibiting elevated refractive indices 1 hour
upon incubation at 37˚C. Therefore, the kinetics of the
increase in refractive index coincided with the kinetics of
the natural collagen gelation. The more positively
charged the collagen, the less gelation was observed.
Because cell surfaces are negatively charged due pri-
marily to the negative charges on the glycoproteins and
the sialic acid of glycolipids, it is believed that the nega-
tively charged cell surfaces can neutralize the positively
charged modified collagen immediately surrounding the
cells, and induce the neutralization of a thin layer of col-
lagen to gel. In other words, a layer of collagen fibers is
expected to form around the cells, soon after the cells
were mixed with the positively charged collagen.
[0060] When the modified collagen was labeled with
a fluorescence dye (Fluorescein isothiocyanate, FITC)
and formed microcapsules with the labeled modified col-
lagen, a layer of collagen fibers was observed around
the cells (Fig. 2B) within 5 minutes. Such collagen fibers
conforming to the shapes of the cells could support the
proliferation and functions of the anchorage-dependent
mammalian cells (such collagen fibers are referred to
herein as the "conformer scaffolds").
[0061] Further away from the cells, the positively
charged modified collagen remained in the liquid state,
or had loose collagen fibers (Fig. 3) not inter-linked as in
a dense gel. Therefore, the liquid collagen could be re-
moved from the cells with a buffer rinse after passing the
microcapsules through a nozzle of approximately 1 mm
inner diameter at a flow rate of 8 ml/min to break the
fragile microcapsule shell. The conformer scaffolds could
remain attached to the individual cells as the cells were
separated from each other. Therefore, anchorage-de-
pendent mammalian cells were harvested non-disrup-
tively (un-disrupted cells) without subjecting them to the
typical disruptive detachment procedures used in con-
ventional 2D cultures.
[0062] The harvested cells were re-encapsulated in
the microcapsules at 1 x 106 cells/ml in 1.5 mg/ml of the
15 16













modified collagen and allowed to proliferate for 7 days.
The PC 12, HepG2, and MSc cells were amplified
150612, 10068, and 8966 times, respectively, in the
microcapsules with slightly modified collagen and
295624, 220619, and 150612 times, respectively, with
highly modified collagen (Fig. 4). Cell amplification was
quantified by calculating the ratio of the final cell density
to the initial cell density (F/I). In Fig. 4, and
represent the F/I values for cells cultured in microcap-
sules with the slightly modified collagen in the completely
dissociated and incompletely dissociated state respec-
tively; and represent the F/I values for cells cul-
tured in microcapsules with highly modified collagen in
the completely dissociated and incompletely dissociated
state respectively. Harvested cells in single cell state re-
proliferated to the full potential while the cell aggregates
exhibited a reduced level of re-proliferation.
[0063] It was conceivable that the aggregation ob-
served in the incompletely dissociated cells could inhibit
cell proliferation. It was found that the completely disso-
ciated cells could re-proliferate to the full potential (as in
Fig. 1) while the incompletely dissociated cells exhibited
a reduced level of re-proliferation (Fig. 4). The highly
modified collagen could enhance the cell amplification
with no significant differences in cell amplification in com-
pletely or incompletely dissociated states (Fig. 4).
[0064] Un-disrupted cells also exhibit better attach-
ment kinetics, cell morphology and functions than the
conventionally cultured cells that were harvested with
disruptive detachment procedures. For tissue engineer-
ing applications, it is highly desirable to transplant har-
vested cells that mimic the characteristics in vivo.
[0065] The characteristics of PC 12 cells and rat hepa-
tocytes cultured on specific ligand-conjugated polymeric
surfaces were examined. Rat hepatocytes were used in
place of HepG2 because rat hepatocytes have well-char-
acterized attachment characteristics to specific ligands.
Rat hepatocytes also have a well-established functional
assay for the cytochrome P450-dependent mono-oxy-
genase activity, which is a good indicator of the detoxi-
fying ability of the cells.
[0066] PC 12 cells interact with the YIGSR peptide-
binding domain of laminin. Rat hepatocytes specifically
bind to motifs on certain sugars, such as lactose and
galactose. The lactose and YIGSR fragment of the lam-
inin were chemically conjugated onto polyester (PET)
membranes and the kinetics of the cell attachment to
these membranes was measured. It was found that the
un-disrupted cells exhibited better attachment kinetics
than the conventionally cultured cells (Fig. 5A-B) on bind-
ing to these ligand-modified polymer surfaces.
[0067] In Fig. 5A, (h) and (■) represent the attachment
of the un-disrupted PC 12 cells onto YIGSR-conjugated
and plain polyester membranes, respectively; (∆) and (m)
represent the attachment of the conventionally cultured
PC 12 cells onto YIGSR-conjugated and plain polyester
membranes, respectively. In Fig. 5B, (s) and (h) repre-
sent the attachment of un-disrupted rat hepatocytes onto
lactose-conjugated PET cover slip, respectively; (e) and
(3) represent the attachment of the conventionally cul-
tured rat hepatocytes onto lactose-conjugated and plain
PET cover slip, respectively. The un-disrupted PC 12
cells and rat hepatocytes were found to exhibit better
attachment to ligand-conjugated PET cover slip than the
conventionally cultured cells.
[0068] The morphology of PC 12 cells changes in re-
sponse to extra-cellular microenvironment. The cell mor-
phology of PC 12 cells was examined as they attached
to the ligand-conjugated PET membranes. Three hours
after the cells were incubated with the membranes, the
cells harvested from conventional culture started to at-
tach with spread morphology (Fig. 5C). In contrast, the
un-disrupted PC 12 cells exhibited the healthy round mor-
phology by binding to significant amount of extracellular
matrices that seemed to have been secreted by the cells
(Fig. 5C). Undifferentiated PC 12 cells normally exhibit
round morphology until after many passages. Therefore,
the un-disrupted cells seem to preserve better cell mor-
phology and matrix-secretion than the conventionally cul-
tured cells.
[0069] In Fig. 5C, the top left panel represents the un-
disrupted PC 12 cells 3 hours after attached to YIGSR-
conjugated PET cover slip; the top right panel represents
the conventionally cultured PC 12 cells. The un-disrupted
PC 12 cells have secreted significant amount of the extra-
cellular matrices than the conventionally cultured cells.
The bottom left panel represents the un-disrupted PC 12
cells 48 hours after nerve growth factor induction; the
bottom right panel represents conventionally cultured PC
12 cells. The maximum length = Σ(length of the longest
neurite on each cell)/n. The mean length =Σ(mean length
of all the neurites on each cell)/n (n=50 cells). The un-
disrupted PC 12 cells show longer neurite extension than
the conventionally cultured cells.
[0070] The PC 12 cells can be induced to form neurites
by nerve growth factor. The maximum and mean lengths
of the neurite extension are good measures of the PC
12 cellular functions. The lengths of the neurites extend-
ed from PC 12 cells 48 hours after induction by nerve
growth factor were measured. It was found that neurites
extended from the undisrupted PC 12 cells were 2-fold
longer, in terms of both maximum and mean lengths,
than the neurites extended from the conventionally cul-
tured PC 12 cells (Fig. 5C).
[0071] The cytochrome P450-dependent mono-oxy-
genase activity of the rat hepatocytes also was meas-
ured. 7-ethoxyresorufin can be converted by the cyto-
chrome P450-dependent mono-oxygenase into a fluo-
rescent product, resorufin. The amount of the fluores-
cence was imaged and quantified using a confocal mi-
croscope. The un-disrupted rat hepatocytes exhibited a
2-fold higher detoxification function than the convention-
ally cultured cells (Fig. 5D) 3 hours after attaching to lac-
tose-conjugated PET membranes. Therefore, the un-dis-
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rupted cells have demonstrated better attachment, mor-
phology, and functions than the conventionally cultured
cells. Fig. 5D illustrates detoxification function of the rat
hepatocytes (as measured by the cytochrome P450-de-
pendent mono-oxygenase activity assay attached onto
the lactose-conjugated PET cover slip). The symbol
represents the detoxification function of the un-disrupted
cells; the symbol represents the conventionally cul-
tured cells. The un-disrupted rat hepatocytes exhibit 2-
fold higher detoxification function than the conventionally
cultured cells 3 hours after attached to the lactose-con-
jugated PET cover slip (n = 150).
[0072] The morphology of the MSC cells on a 2D cul-
ture changes with response to the numbers of passages
and tend to undergo spontaneous differentiation. The
morphology of the un-disrupted cells and the convention-
ally culture 2D cells were observed as they attached onto
the tissue culture polystyrene dish after a month of con-
tinuous culture. In a suitable environment, the heteroge-
neous cell populations can differentiate into several lin-
eages depending on the induction factors and environ-
ments. One typical characteristic of these cells cultured
in 2D is that they have limited proliferative capacity (from
about 7-13 passages). Most cells exhibit a slowed pro-
liferation (increasing doubling time) after about 10 pas-
sages, and almost completely stop proliferation after
about 12 or 13 passages. After that time, the cells ran-
domly differentiate and lift up from the culture dish and
float up into culture media (Fig. 5E). The cells typically
have a doubling time of about 48 hours, i.e., the cells can
proliferate for about 212 (= 4096) folds per isolation from
bone marrow when cultured in 2D.
[0073] In Fig. 5E, the left panel represents the 2D cells
at passage 5, 48 hours upon attachment tissue culture
polystyrene dish. The middle panel represents the un-
disrupted cells at passage 11, 48 hours upon attachment
onto tissue culture polystyrene dish. The right panel rep-
resents the 2D cells at passage 14, which have shown
a decrease in rate of proliferation. The un-disrupted cells
and the 2D cells assume the well-spread morphology at
confluency. Fig. 5F illustrates the doubling time of the
cells. The symbol represents the doubling time of
the un-disrupted cells. The symbol represents the
doubling time of the conventionally cultured cells.
[0074] When the cells were cultured in the 3D system
of the present invention, about a 100- to 160-fold ampli-
fication was observed in 5-7 days. Thus, the doubling
time was reduced to about 24 hours in the microcapsules.
These cells were cultured in microcapsules for 35 days,
which is equivalent to a 235 (~3.4 x 1010)-fold amplifica-
tion. In terms of the age of the cells, such amplification
is equivalent to about 35 passages in 2D culture. At the
time of filing of this application, the cells were still prolif-
erating in microcapsules as readily (e.g., with the same
steady rate) as when they were first isolated from the
bone marrow. When these cells were plated onto a 2D
culture plate, they exhibited the same morphology, and
the same doubling time (48 hours) in 2D culture as those
cells freshly isolated (in contrast to the cells cultured in
2D culture for 12 passages, which then stopped prolifer-
ation).
[0075] The three-dimensional cell culture system of
the present invention can greatly extend the proliferative
capacity of many primary cells isolated from tissues, es-
pecially those precursors and various stem cells from
bone marrow and other possible sources such as cord
blood, adult blood, fat, etc., for truly large-scale produc-
tion of such cells. This in turn will greatly facilitate or made
possible the various applications (e.g., transplantation,
tissue engineering, etc.) using autologous or allogenic
cell sources. If sufficient adult stem cells can be amplified
for various applications, this potentially overcomes one
of the primary limitations of adult stem (AS) cells, which
in turn could avoid the ethically complicated use of em-
bryonic stem (ES) cells altogether.
[0076] Tissue engineering applications can greatly
benefit from the un-disrupted cells obtained by the 3D
culture of the present invention. Numerous efforts have
been undertaken to develop and improve cell attach-
ment. It is believed that the un-disrupted cells exhibiting
the improved attachment kinetics can complement these
efforts. The requirements for cells to recover from the
typical detachment damages experienced by the con-
ventionally cultured cells are avoided so that the un-dis-
rupted cells can interact with the engineered biomaterials
surfaces immediately after harvesting. Multiple types of
cells can be seeded sequentially within a short period of
time to better control the formation of complex tissue con-
structs. These un-disrupted cells also have intact cell sur-
face receptors and other membrane components that
can enhance the interaction between these un-disrupted
cells and other cells or extra-cellular matrices to generate
functioning tissues when transplanted in vivo for tissue
repair and regeneration.
[0077] Furthermore, the microencapsulated cells can
be cultured in well-established macro-environments
such as the packed-bed and fluidized-bed bioreactors
for large-scale production of highly functional anchorage-
dependent cells for various applications.
EXAMPLE
[0078] The following example is illustrative of preferred
aspects of the invention and should not be construed to
limit the claims in any way. The example illustrates pre-
paring a three-dimensional cell culture with hepatocyte,
PC 12, and MSc cells. All reagents were purchased from
Sigma-Aldrich unless otherwise indicated.
Ter-polymer preparation
[0079] Ter-polymer of methacrylic acid (MAA), 2-hy-
droxyethyl methacrylate (HEMA), and methyl methacr-
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ylate (MMA) was synthesized by solution polymerization
in 2-propanol using 2,2’-azobisisobutyronitrile (AIBN) as
initiator. The monomers were distilled under nitrogen at
reduced pressure. The polymerization was performed
with an initiator concentration of 0.1 mol% of monomers
under nitrogen with a magnetic stirrer at 78˚C in an oil
bath. The molar feed ratio of MAA, HEMA, and MMA was
fixed at 25:25:50 or other ratios as desired and the ratio
of total monomer to solvent at 1:6 (W/V). The reaction
was allowed to proceed for overnight and quenched by
cooling to room temperature. The polymer was precipi-
tated by addition to a large excess of petroleum ether.
The precipitate was re-dissolved in a minimum volume
of ethanol, and re-precipitated in distilled water. Recov-
ered polymer then was dissolved in a 1 M sodium hy-
droxide solution, and further purified by repeated dialysis
against distilled water with MWCO of 3500, and lyophi-
lized. The yield of the polymer was found to be ~ 63%.
The polymer composition was determined by proton
NMR and the molar ratio of MAA, HEMA, and MMA was
found to be 20.4:27.4:52.2 for the molar feed ratio of 25:
25:50. The molecular weight of the ter-polymer before
dialysis was determined by GPC (with THF as eluent) to
be 30,000.
Modification of Collagen at 4˚C
[0080] Collagen can be modified to be cationic and
anionic by the removal of either the negative or the pos-
itive charge from the collagen chains. In this case, cati-
onic collagen was obtained through the modification of
the carboxyl group by esterification with low molecular
weight alcohol. 20 ml of stock solution (3 mg/ml) of col-
lagen (Vitrogen 100, Collagen Corp., Palo Alto, CA) was
first precipitated with 400 ml of acetone. The precipitated
collagen was dissolved in 200 ml of 0.1 M HCl containing
methanol (Merck), stirred at 4˚C for 6 days under sterile
conditions. The lyophilized modified collagen can then
be stored up to 6 months in -20˚C in the presence of
desiccant. The modification was monitored by titration.
Titration of the natural collagen gave a typical titration
curve of a mixed acid or a dibasic acid, while that of mod-
ified collagen gave a typical titration curve of a week
monobasic acid, indicating that most carboxyl groups
have been esterified in modified collagen. In addition,
neutralization of the modified collagen needs less sodium
hydroxide than that of the natural collagen, indicating that
the polymer chain of the modified collagen has less ionic
groups because of the esterification of the carboxyl
groups.
Modification of collagen at room temperature
[0081] Collagen can be modified to be cationic and
anionic by the removal of either the negative or the pos-
itive charge from the collagen chains. In this case, cati-
onic collagen was obtained through the modification of
the carboxyl group by esterification with low molecular
weight alcohol (e.g. methanol). 20 ml of stock solution (3
mg/ml) collagen (Vitrogen 1000, Collagen Corp., Palo
Alto, CA) was first precipitated with 400 ml of acetone.
The precipitated collagen was dissolved in 200 ml of 0.1
M HCl containing methanol (Merck), stirred at room tem-
perature for various amount of time (3, 6, 24 & 48 hours)
under sterile conditions. The modified collagen solution
was dialyzed for 2 days until the pH reached 5 and lyophi-
lized. The lyophilized modified collagen can then be
stored up to 6 months in -20˚C in the presence of desic-
cant. The degree of modification was monitored by titra-
tion. Titration of the natural collagen gave a typical curve
of a mixed acid or a dibasic acid, while that of modified
collagen gave a typical titration curve of a weak mono-
basic acid, indicating that most carboxyl groups have
been esterified in modified collagen. In addition, neutral-
ization of the modified collagen needs less sodium hy-
droxide than that of the natural collagen, indicating that
the polymer chain of the modified collagen has less car-
boxylic protons because of the esterification of these car-
boxyl groups. The collagen modified at room temperature
has a higher degree of freedom in terms of the amount
of positive charges than those modified at 4˚C as de-
scribed previously. This allows a wider range of collagen
concentrations to be used to form microcapsules since
the previous microcapsules are limited by the charges
on modified collagen.
Isolation of Hepatocytes
[0082] Hepatocytes were harvested from male, Wistar
rat, weighing from 250-300 g by a 2-step in situ colla-
genase perfusion as described previously with some
modifications. The rat was given 100 U/kg of heparin 30
minutes before anesthesia. Pentobarbital was adminis-
tered at a dose of 30 mg/kg, intra-peritoneally at the start
of the operation. After laparotomy, a portal cannula was
placed and fixed in a position along the portal vein. A cut
was rapidly made in the lower vena cava. In the first 2-3
minutes, pre-perfusion (with Ca2+-free perfusion buffer)
was performed while the liver remained in situ. The per-
fusate flow was started at a rate of 50 ml per minute.
While pre-perfusion was carried out, the liver was trans-
ferred to a petri-dish and placed in a position similar to
its in situ site. After 10 minutes of pre-perfusion with
Ca2+-free medium, the liver was then perfused with re-
circulating 0.05% collagenase buffer for another 10 min-
utes. This was terminated when the vena cava ruptured.
The entire perfusion procedure was performed under ox-
ygenation that greatly improved the cell viability. The cells
were liberated from the connective vascular tissue and
re-suspended in fresh growth medium. This was followed
by incubation of the cell suspension in a 37˚C CO2 incu-
bator for 30 minutes. The cell suspension was then fil-
tered through a nylon mesh with a 60 mm pore size to
further remove the connective tissue debris. The filtrate
was then centrifuged at 50 g for 1 minute to obtain the
cell pellet The cells were collected and washed twice with
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growth medium. The viability of the hepatocytes was de-
termined to be 90-95% in all cases using the conventional
Trypan Blue exclusion test.
Preparation of microencapsulated PC-12 cells
[0083] Microencapsulation was performed at room
temperature with the aid of a syringe pump (IVAC P6000,
Alaris Medical Systems, San Diego, CA). The PC-12 cells
were suspended in a modified collagen solution that was
prepared by first dissolving the lyophilized modified col-
lagen in Phosphate Buffered Saline (PBS) to obtain a
collagen concentrations of 0.5, 1.0, and 1.5 mg/ml. The
cell suspension was maintained at 4˚C before the exper-
iment to prevent the gelation of the collagen solution. The
PC-12 cells suspension was extruded from a 30.5-gauge
needle attached to the syringe pump at various flow rates
suitable into a 10%-17% ter-polymer solution unless oth-
erwise stated. Thus, the positively charged collagen mol-
ecules bound to the negatively charged ter-polymer mol-
ecules at the outer surface of the microcapsules to form
a polyelectrolyte complex. The microcapsules were in-
cubated at 37˚C for an hour to allow the collagen to gel
before the microcapsules were harvested by sedimen-
tation method and washed twice with 1X PBS for further
culturing.
[0084] Modifying the charges of the positively charged
collagen and the concentration of the negatively charged
ter-polymer controls the thickness of the ter-polymer
shell. A 0.5 mg/ml collagen has less positive charges
than a 1.5 mg/ml collagen. The thickness of the ter-pol-
ymer shell in the range of 2-5 mm was found to provide
optimal mass transport properties. Therefore, 10% of the
ter-polymer is needed to complex coacervate 0.5 mg/ml
collagen but 17% ter-polymer is needed to complex coac-
ervate 1.5 mg/ml collagen to form 2-5 mm shell. If a 10%
ter-polymer is used for 1.5 mg/ml collagen with high
charge density (modified at room temperature for one
day), then a much thicker shell is formed which impedes
the mass transport properties and leads to central necro-
sis at center of the microcapsules.
Preparation of microencapsulated hepatocytes
[0085] Microencapsulation was performed at room
temperature with the aid of a syringe pump. Briefly, the
hepatocytes were suspended in a modified collagen so-
lution that was prepared by first dissolving the lyophilized
modified collagen in Phosphate Buffered Saline (PBS)
to obtain a collagen concentration of 1.5 mg/ml. The
hepatocyte suspension was maintained at 4˚C before the
experiment to prevent the gelation of the collagen solu-
tion. The hepatocyte suspension was extruded from an
18© gauge needle attached to a syringe pump at various
flow rates into 10% ter-polymer solution. Thus, the pos-
itively charged collagen molecules bound to the nega-
tively charged ter-polymer molecules at the outer surface
of the microcapsules to form a polyelectrolyte complex.
The microcapsules were incubated at 37˚C for one hour
to allow the collagen to gel before the microcapsules
were harvested by sedimentation method and washed
twice with 1 x PBS for further culturing.
Cell Culture
[0086] The microencapsulated cells were cultured for
the required amount of time in 35mm polystyrene dishes
in a humidified atmosphere at 37˚C with 5% CO2. Culture
media [PC12: DMEM supplemented with 5% horse se-
rum (GIBCO Laboratories, Chagrin Falls, OH) and 10%
fetal bovine serum (GIBCO Laboratories, Chagrin Falls,
OH); HepG2: DMEM supplemented with 10% fetal bo-
vine serum; rabbit mesenchymal stem cells: DMEM sup-
plemented with 15% fetal bovine serum and 1500mg/L
of glucose and rat hepatocytes: Hepatozym-SFM (GIB-
CO Laboratories, Chagrin Falls, OH)] were replaced eve-
ry two days. Conventional culture of the cells in 2D were
performed as described in (1) Jauregui, "Cell Adhesion
to Biomaterials: The Role of Several Extracelluar Matrix
Components in the Attachment of Non-transformed Fi-
brolasts and Parenchymal Cells," ASAIO Trans 33,
66-74 (1987); (2) Gutsche, A.T. et al., "Rat Hepatocyte
Morphology and Function on Lactose-Derivatized Poly-
styrene Surfaces," Biotechnology and Bioengineering
49, 259-265 (1996); and (3) Hu, M.Y. et al., "Effects of
Hepatocytes Growth Factor on Viability and Biotransfor-
mation Functions of Hepatocytes in Gel Entrapped and
Monolayer Culture," Crit Care Med 23, 1237-1242
(1995).
[0087] PC12 and HepG2 cells were purchased from
ATCC. Rat hepatocytes were isolated as described in
Chia, S.M. et al., "Hepatocyte Encapsulation for En-
hanced Cellular Functions," Tissue Eng 5, 481-496
(2000). Mesenchymal stem (MSC) cells enriched low
density bone marrow mononuclear cells (BMMNC) were
isolated as follows: Bone marrow was aspirated from iliac
crest of NZW rabbits and collected into 50 ml polypro-
pylene tubes with 1000 units/mil preservative-free
heparin and thoroughly mixed. Low density BMMNCs
were by density gradient centrifugation over Ficoll
(1.077g/ml) at 400xg for 30 minutes. The BMMNC layers
were removed by pipette and rinsed in PBS, and cultured
in suitable media as described above.
Cell splitting and harvesting
[0088] The un-disrupted cells were harvested from the
microcapsules by passing the microcapsules through a
1 mm diameter plastic nozzle at a flow rate of 8 ml/min.
The cells released from the microcapsules were centri-
fuged at 80x g for 1 minute to remove the large pieces
of the broken microcapsule shell. The supernatant con-
taining the cells released from the broken microcapsules
were collected and centrifuged for an additional 3 min-
utes at 800x g to remove the liquid collagen. The cell
pellets were rinsed with buffer, i.e., re-suspended in
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phosphate buffered saline (PBS) and re-centrifuged
again. The cell pellets were then re-suspended in fresh
culture media for re-proliferation or use immediately for
applications. The number of cells amplified was deter-
mined by counting the cells released from the microcap-
sules with the aid of a hemocytometer.
Light Microscope Imaging of the Microcapsules
[0089] Live cells were imaged with a confocal micro-
scope (Olympus FLUOVIEW 300, Tokyo). To visualize
the formation of the "conformer scaffolds", the modified
collagen was labeled with FITC by dissolving 1 mg of
FITC in 10 mL of 1.5 mg/mL modified collagen solution
overnight, followed by extensive dialysis for 24 hours to
remove the unlabelled FITC molecules. The lyophilized
labeled collagen can be stored in -20˚C in darkness for
up to 6 months. The microcapsules were processed for
scanning electron microscopy and imaged with a JOEL
5600 LV SEM.
Peptide conjugation to PET membranes
[0090] Thermanox cover slips (PET cover slip, NUNC,
Naperville, IL, USA) were cleaned by rinsing with sol-
vents (in a sequence of Water-Methanol-Hexane-Meth-
anol-Water). Clean cover slips were placed into 24-well
culture plates containing 1 M NaOH (1 ml) in each well
and hydrolyzed for 4 hours at room temperature with
shaking. The cover slips were then rinsed several times
with 1 M HCl and distilled water. The resulting cover slips
were treated in a mixed solution, which contains 0.1 M
MES, 1 mg/ml NHS, 10 mg/ml EDC and 0.5 mg/ml YIGSR
peptide for more than 4 hours on a platform shaker. Fi-
nally, the cover slips were rinsed with PBS once and with
4 N NaCl 3 times, then with PBS for several times before
use.
Lactose conjugation to PET membranes
[0091] Thermanox cover slips were first aminated by
incubating with 50% aqueous ethylene diamine solution
for 8 hours at 40˚C, and rinsed with excess amount of
tetrahydrofuran and de-ionized water. The aminated PET
cover slips were then incubated in 0.1M sodium borate
buffer (pH 9.3) containing 10 mg/ml lactose and 10 mg/ml
sodium cyanoborohydride at 40˚C for 48 hours followed
by extensive rinsing with 4 N NaCl and de-ionized water.
The amount of the lactose/galactose conjugated to the
PET membranes was determined by counting the 14C-
labelled lactose (ICN Biomedicals, Inc., Aurora, Ohio) in
the reaction. Cells attached to the membranes were
quantified by counting the percentage of unattached cells
among the total number of cells incubated with the mem-
branes.
Morphological Assay
[0092] Mesenchymal stem cells harvested from the mi-
crocapsules or the 2D culture were seeded onto 35mm
tissue culture dishes and incubated for 48 hours in 37˚C
with 5% CO2. The morphology of the cells was imaged
with an inverted microscope with Hoffman optics.
Functional assays
[0093] PC 12 cells harvested from the microcapsules
or 2D culture were seeded onto collagen-coated mem-
branes and induced with 20 ng/ml of nerve growth factor
(Baldwin, S.P. et al., "PC12 Cell Aggregation and Neurite
Growth in Gels of Collagen, Laminin and Fibronectin,"
Int J Dev Neurosci 14, 351-364 (1996)) for 48 hours. The
cells were fixed with 3.7% Formalin for 10 minutes, im-
aged and the maximum and the mean neurite lengths
quantified with a confocal microscope. The cytochrome
P450-dependent mono-oxygenase activity of rat hepa-
tocytes was measured. Data from three independent ex-
periments were analyzed and values are represented as
mean 6 standard error of means.
Claims
1. A non-disruptive three-dimensional system for cul-
turing one or more anchorage-dependent cell types,
the system comprising a plurality of hollow micro-
capsules each containing an inner extracellular ma-
trix in contact with at least one cell and an outer shell
of synthetic polymer surrounding the extracellular
matrix;
wherein cells in contact with the extracellular matrix
are cultured in three dimensions inside of the hollow
microcapsules;
wherein said microcapsules are permeable to nutri-
ents necessary to sustain normal metabolic func-
tions of the cells and to toxins released by the cells;
and
wherein said outer shell has a thickness of from
about 1 to about 20 mm and is rupturable with me-
chanical agitation to harvest the cultured cells.
2. The cell culture system of claim 1 wherein the ratio
of the number of cells at the end of a culture period
to the number of initially seeded cells is at least 10:1.
3. The cell culture system of claim 1 wherein said ex-
tracellular matrix is selected from the group consist-
ing of cationic collagen, anionic collagen, anionic es-
terified hyaluronic acid, anionic amine-modified hy-
aluronic acid, fibronectin, and laminin.
4. The cell culture system of claim 3 wherein said ex-
tracellular matrix comprises a cationic collagen at a
concentration of from about 0.2 to about 3.5 mg/ml.
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5. The cell culture system of claim 1 wherein said syn-
thetic polymer comprises an acrylate ter-polymer of
methacrylic acid, hydroxyethyl methacrylate, and
methyl methacrylate.
6. The cell culture system of claim 1 wherein said an-
chorage-dependent cells comprise one or more cell
types selected from the group consisting of pheo-
chromocytoma cells, hepatocyte cells, and mesen-
chymal stem cells.
7. The cell culture system of claim 1 wherein said an-
chorage-dependent cells comprise at least two cell
types or at least three cell types.
8. A method of culturing anchorage-dependent cells in
a three-dimensional cell culture system comprising:
encapsulating anchorage-dependent cells in a
hollow microcapsule comprising an inner extra-
cellular matrix surrounding at least one cell and
an outer shell of synthetic polymer surrounding
and supporting the matrix; wherein cells in con-
tact with the extracellular matrix are cultured in
three dimensions inside of the hollow microcap-
sule; wherein said microcapsule is permeable
to nutrients necessary to sustain normal meta-
bolic functions of the cells and to toxins released
by the cells; and wherein said outer shell has a
thickness of from about I to about 20 mm;
applying agitation to the microcapsule after a
predetermined time to rupture the outer shell;
and
removing the extracellular matrix to recover the
cells.
9. The method of claim 8 wherein the ratio of the
number of cells at the end of a culture period to the
number of initially seeded cells is at least 10:1.
10. The method of claim 8 wherein said extracellular ma-
trix is selected from the group consisting of cationic
collagen, anionic collagen, anionic esterified hy-
aluronic acid, anionic amine-modified hyaluronic ac-
id, fibronectin, and laminin.
11. The method of claim 8 wherein said extracellular ma-
trix comprises a cationic collagen at a concentration
of from about 0.2 to about 3.5 mg/ml.
12. The method of claim 8 wherein said synthetic poly-
mer comprises an acrylate ter-polymer of methacryl-
ic acid, hydroxyethyl methacrylate, and methyl meth-
acrylate.
13. The method of claim 8 wherein said anchorage-de-
pendent cells comprise one or more cell types se-
lected from the group consisting of pheochromocy-
toma cells, hepatocyte cells, and mesenchymal stem
cells.
14. The method of claim 8 wherein said anchorage-de-
pendent cells comprise at least two cell types or at
least three cell types.
Patentansprüche
1. Ein die Intaktheit von Zellen nicht angreifendes, drei-
dimensionales System für die Kultivierung einer oder
mehrerer verankerungsabhängiger Zelltypen, wobei
das System eine Mehrzahl an hohlen Mikrokapseln
aufweist, von denen jede eine innere Extrazellular-
matrix in Kontakt mit mindestens einer Zelle und eine
äußere Schale aus synthetischem Polymer, die die
Extrazellularmatrix umgibt, aufweist,
wobei Zellen im Kontakt mit der Extrazellularmatrix
in drei Dimensionen im Inneren der hohlen Mikro-
kapseln kultiviert werden,
wobei die Mikrokapseln durchlässig sind für Nähr-
stoffe, die notwendig sind, um normale metabolische
Funktionen der Zellen zu gewährleisten, und für von
den Zellen freigesetzte Toxine und
wobei die äußere Schale eine Dicke von etwa 1 bis
etwa 20 mm hat und durch mechanische Bewegung
zerbrochen werden kann, um die kultivierten Zellen
zu ernten.
2. Zellkultursystem nach Anspruch 1, wobei das Ver-
hältnis der Zellzahl am Ende des Kulturzeitraums
zur Zahl der anfänglich ausgesäten Zellen minde-
stens 10:1 beträgt.
3. Zellkultursystem nach Anspruch 1, wobei die Extra-
zellularmatrix aus der Gruppe ausgewählt wird, die
aus kationischem Kollagen, anionischem Kollagen,
anionischer veresterter Hyaluronsäure, anionischer
amin-modifizierter Hyaluronsäure, Fibronectin und
Laminin besteht.
4. Zellkultursystem nach Anspruch 3, wobei die Extra-
zellularmatrix ein kationisches Kollagen in einer
Konzentration von etwa 0,2 bis etwa 3,5 mg/ml auf-
weist.
5. Zellkultursystem nach Anspruch 1, wobei das syn-
thetische Polymer ein Acrylat-Terpolymer aus Me-
thacrylsäure, Hydroxyethylmethacrylat und Methyl-
methacrylat aufweist.
6. Zellkultursystem nach Anspruch 1, wobei die veran-
kerungsabhängigen Zellen einen oder mehr Zellty-
pen aufweisen, die aus der Gruppe ausgewählt sind,
die aus Pheochromocytomzellen, Hepatocytenzel-
len und mesenchymalen Stammzellen besteht.
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7. Zellkultursystem nach Anspruch 1, wobei die veran-
kerungsabhängigen Zellen mindestens zwei Zellty-
pen oder mindestens drei Zelltypen aufweisen.
8. Verfahren zur Kultivierung verankerungsabhängiger
Zellen in einem dreidimensionalen Zellkultursystem,
das umfasst:
Einkapseln von verankerungsabhängigen Zel-
len in einer hohlen Mikrokapsel, die eine innere
Extrazellularmatrix, welche mindestens eine
Zelle umgibt, und eine äußere Schale aus syn-
thetischem Polymer aufweist, welche die Matrix
umgibt und stützt, wobei Zellen im Kontakt mit
der Extrazellularmatrix in drei Dimensionen im
Inneren der hohlen Mikrokapsel kultiviert wer-
den, wobei die Mikrokapsel durchlässig ist für
Nährstoffe, die notwendig sind, um normale me-
tabolische Funktionen der Zellen zu gewährlei-
sten, und für von den Zellen freigesetzten Toxi-
ne, und wobei die äußere Schale eine Dicke von
etwa 1 bis etwa 20 mm hat,
Ausüben einer Bewegung nach einer zuvor fest-
gelegten Zeit, auf die Mikrokapsel, um die äu-
ßere Schale zu zerbrechen, und
Entfernen der Extrazellularmatrix, um die Zellen
zu gewinnen.
9. Verfahren nach Anspruch 8, wobei das Verhältnis
der Zellzahl am Ende des Kulturzeitraums zur Zahl
der anfänglich ausgesäten Zellen mindestens 10:1
beträgt.
10. Verfahren nach Anspruch 8, wobei die Extrazellular-
matrix aus der Gruppe ausgewählt wird, die aus kat-
ionischem Kollagen, anionischem Kollagen, anioni-
scher veresterter Hyaluronsäure, anionischer amin-
modifizierter Hyaluronsäure, Fibronectin und Lami-
nin besteht.
11. Verfahren nach Anspruch 8, wobei die Extrazellular-
matrix ein kationisches Kollagen in einer Konzentra-
tion von etwa 0,2 bis etwa 3,5 mg/ml aufweist.
12. Verfahren nach Anspruch 8, wobei das synthetische
Polymer ein Acrylat-Terpolymer aus Methacrylsäu-
re, Hydroxyethylmethacrylat und Methylmethacrylat
aufweist.
13. Verfahren nach Anspruch 8, wobei die veranke-
rungsabhängigen Zellen einen oder mehr Zelltypen
aufweisen, die aus der Gruppe ausgewählt sind, die
aus Pheochromocytomzellen, Hepatocytenzellen
und mesenchymalen Stammzellen besteht.
14. Verfahren nach Anspruch 8, wobei die veranke-
rungsabhängigen Zellen mindestens zwei Zelltypen
oder mindestens drei Zelltypen aufweisen.
Revendications
1. Système tridimensionnel non perturbateur pour cul-
tiver un ou plusieurs types de cellules dépendantes
d’un support, le système comprenant une pluralité
de microcapsules creuses, chacune contenant une
matrice extracellulaire interne en contact avec au
moins une cellule et une coque externe de polymère
synthétique entourant la matrice extracellulaire ;
dans lequel les cellules en contact avec la matrice
extracellulaire sont cultivées en trois dimensions à
l’intérieur des microcapsules creuses ;
dans lequel lesdites microcapsules sont perméables
aux nutriments nécessaires pour soutenir les fonc-
tions métaboliques normales des cellules et aux toxi-
nes libérées par les cellules ; et
dans lequel ladite coque externe a une épaisseur
d’environ 1 à environ 20 mm et peut être rompue par
agitation mécanique pour récolter les cellules culti-
vées.
2. Système de culture cellulaire selon la revendication
1 dans lequel le rapport du nombre de cellules à la
fin d’une période de culture au nombre de cultures
ensemencées initialement est d’au moins 10:1.
3. Système de culture cellulaire selon la revendication
1 dans lequel ladite matrice extracellulaire est sé-
lectionnée dans le groupe consistant en le collagène
cationique, le collagène anionique, l’acide hyaluro-
nique anionique estérifié, l’acide hyaluronique anio-
nique modifié par amine, la fibronectine et la lamini-
ne.
4. Système de culture cellulaire selon la revendication
3 dans lequel ladite matrice extracellulaire comprend
un collagène cationique à une concentration d’envi-
ron 0,2 à environ 3,5 mg/ml.
5. Système de culture cellulaire selon la revendication
1 dans lequel ledit polymère synthétique comprend
un terpolymère d’acrylate d’acide méthacrylique,
l’hydroxyéthylméthacrylate et le méthacrylate de
méthyle.
6. Système de culture cellulaire selon la revendication
1 dans lequel lesdites cellules dépendantes d’un
support comprennent un ou plusieurs types de cel-
lules choisis dans le groupe consistant en les cellules
de phéochromocytome, les hépatocytes et les cel-
lules souches mésenchymateuses.
7. Système de culture cellulaire selon la revendication
1 dans lequel lesdites cellules dépendantes d’un
support comprennent au moins deux types de cel-
lules ou au moins trois types de cellules.
8. Procédé pour cultiver des cellules dépendantes d’un
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support dans un système de culture cellulaire tridi-
mensionnel comprenant les étapes consistant à :
encapsuler des cellules dépendantes d’un sup-
port dans une microcapsule creuse comprenant
une matrice extracellulaire interne entourant au
moins une cellule et une coque externe de po-
lymère synthétique entourant et soutenant la
matrice ; dans lequel les cellules en contact
avec la matrice extracellulaire sont cultivées en
trois dimensions à l’intérieur de la microcapsule
creuse ; dans lequel ladite microcapsule est per-
méable aux nutriments nécessaires pour sou-
tenir les fonctions métaboliques normales des
cellules et aux toxines libérées par les cellules ;
et dans lequel la coque externe a une épaisseur
d’environ 1 à environ 20 mm ;
appliquer une agitation à la microcapsule après
une durée prédéterminée pour rompre la coque
externe; et
éliminer la matrice extracellulaire pour récupé-
rer les cellules.
9. Procédé selon la revendication 8 dans lequel le rap-
port du nombre de cellules à la fin d’une période de
culture au nombre de cellules ensemencées initia-
lement est d’au moins 10:1.
10. Procédé selon la revendication 8 dans lequel ladite
matrice extracellulaire est choisie dans le groupe
consistant en le collagène cationique, le collagène
anionique, l’acide hyaluronique anionique estérifié,
l’acide hyaluronique anionique modifié par amine, la
fibronectine et la laminine.
11. Procédé selon la revendication 8 dans lequel ladite
matrice extracellulaire comprend un collagène ca-
tionique à une concentration d’environ 0,2 à environ
3,5 mg/ml.
12. Procédé selon la revendication 8 dans lequel ledit
polymère synthétique comprend un terpolymère
d’acrylate d’acide méthacrylique, l’hydroxyéthylmé-
thacrylate et le méthacrylate de méthyle.
13. Procédé selon la revendication 8 dans lequel lesdi-
tes cellules dépendantes d’un support comprennent
un ou plusieurs types de cellules choisis dans le
groupe consistant en les cellules de phéochromocy-
tome, les hépatocytes et les cellules souches mé-
senchymateuses.
14. Procédé selon la revendication 8 dans lequel lesdi-
tes cellules dépendantes d’un support comprennent
au moins deux types de cellules ou au moins trois
types de cellules.
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